Search results

ANSTO’s nuclear medicine processing and distribution facility assembles, loads, tests and distributes a range of nuclear medicine products, including Mo-99. The Mo-99 is dispensed into an ANSTO radiopharmaceutical Gentech® Generator where it decays to Tc-99m.

Research on the mechanism of cell death has insights to bring progress on neurodegenerative diseases and plant biosecurity.

ANSTO's unique capabilities are being used to develop a quick analytical tool to determine the geographic origin of seafood and authenticates quality.

Detailed molecular structure of silver nanocrystals determined

ANSTO continually monitors environmental gamma radiation from a station located in Engadine NSW. ANSTO uses environmental radiation data to evaluate atmospheric dispersion from its site. This radiation is almost completely natural background radiation.

Imaging protocol assesses molecular mechanism of work in the treatment of deadly childhood cancer neuroblastoma.

Researchers developing new materials and devices that can withstand the harsh radiation environment in space are using the unique ANSTO’s capability to simulate the effects of high-energy ion irradiation on the properties and performance of these materials and devices.

The protein mapping workhorses of the Australian Synchrotron, Macromolecular and Microfocus crystallography beamlines, MX1 and 2, continue to support important biomedical research in the development of vaccines and new therapeutics.

Developed by ANSTO’s predecessor the Australian Atomic Energy Commission (known as the AAEC) in the late 1960s, the Technetium-99m Generator revolutionised nuclear medicine imaging in Australia by enabling imaging procedures to be performed not only in major capital cities but throughout regional and rural Australia.